Department of Pediatric Endocrinology and Diabetology and Reference Center for rare Diseases of Growth and Development, CHU Robert-Debre, 75019 Paris, France.
Endocrine, Bone Diseases, Genetics, Obesity, and Gynecology Unit, Children's Hospital, University Hospital, 31000 Toulouse, France.
Ann Endocrinol (Paris). 2018 Dec;79(6):647-655. doi: 10.1016/j.ando.2018.08.001. Epub 2018 Aug 16.
R1 The diagnosis of Graves' disease in children is based on detecting a suppression of serum TSH concentrations and the presence of anti-TSH receptor antibodies. 1/+++. R2 Thyroid ultrasound is unnecessary for diagnosis, but can be useful for assessing the size and homogeneity of the goiter. 2/+. R3. Thyroid scintigraphy is not required for the diagnosis of Graves' disease. 1/+++. R4. The measurement of T4L and T3L levels is not necessary for the diagnosis of Graves' disease in children but can be useful for the management and assessment of prognosis. 1/++. R5. In the absence of TSH receptor autoantibodies, the possibility of genetically inherited hyperthyroidism must be considered. 1/++. R6. Drug therapy is the primary line of treatment for children and consists of imidazole, carbimazole or thiamazole, with an initial dosage of 0.4 to 0.8mg/kg/day (0.3 to 0.6mg/kg/day for thiamazole) depending on the initial severity, up to maximum of 30mg. 1/++. R7. Propylthiouracil is contraindicated for children with Grave's disease. 1/+++. R8. Before starting treatment, it may be useful to perform a CBC in order to assess the degree of neutropenia caused by hyperthyroidism. It is not necessary to perform systematic CBCs during follow-up. 2/+. R9. An emergency CBC should be performed if symptoms include fever or angina. If neutrophil counts are <1000/mm, synthetic antithyroid therapy should be discontinued or decreased and may be permanently contraindicated in severe (<500) and persistent neutropenia. Otherwise treatment may be resumed. 1/++. R10. Transaminases levels should be measured before initiating treatment. Systematic monitoring of liver function is not consensually validated. 2/+. R11. In cases of jaundice, digestive disorders or pruritus, measuring liver enzymes (AST, ALT), total and conjugated bilirubin and alkaline phosphatases is indicated. 1/++. R12. Patients and parents should be informed of the possible side effects of antithyroid agents. 1/+. R13. Therapeutic education of parents and children is important in ensuring the best possible treatment compliance. 2/++. R14. Given the specificities involved in the treatment of Graves' disease in children, medical care should be provided by a specialist accustomed to treating endocrinopathies in pediatric patients. 2/+. R15. Depending on patient age, the severity of the disease at diagnosis and the persistence of anti-TSH receptor antibodies, the initial course of treatment must take place over an extended period of 3 to 6 years. R16.The anticipated success rates of medical treatment (50% of patients in remission following several years of treatment) should be explained to the family and the child. The possibility that radical treatment may be required in case of failure or intolerance of medical treatment should also be discussed. 1/++. R17.In females with Graves' disease, it is important to explain that they must undergo an assessment by an endocrinologist before planning future pregnancies, from the start of pregnancy and during the course of pregnancy. This is true in all female patients, even those in remission after medical treatment, or those who have undergone radical treatment. R18.Indications for a radical treatment can arise in cases of: 1/+: contraindication to antithyroid agents; poorly controlled hyperthyroidism due to lack of compliance; relapse despite prolonged medical treatment; a request made by the family and child for personal reasons. R19.Surgery is the radical method of treatment used in children under 5 years of age, or in cases of very large, nodular, or compressive goiters. 2/++. R20. The surgeon's experience in dealing with thyroidectomies in children is likely to be the most significant determining factor in limiting the morbidity of the procedure (alongside any collaboration between a pediatric surgeon and an adult surgeon). 1/++. R21 When radical treatment is indicated, I-131 treatment may be discussed after 5 years (but more often after puberty), if the goiter is not too large. Experience from monitoring Graves' disease in North American children is reassuring. 1/++.
儿童格雷夫斯病的诊断基于检测血清 TSH 浓度的抑制和抗 TSH 受体抗体的存在。1/+++。
甲状腺超声对于诊断不是必需的,但对于评估甲状腺肿的大小和均匀性可能有用。2/+。
放射性碘治疗不是诊断格雷夫斯病所必需的。1/+++。
对于儿童格雷夫斯病,测量 T4L 和 T3L 水平不是必需的,但对于管理和评估预后可能有用。1/+++。
在没有 TSH 受体自身抗体的情况下,必须考虑遗传性甲状腺功能亢进症的可能性。1/+++。
药物治疗是儿童的主要治疗方法,包括咪唑、卡比马唑或他唑,初始剂量为 0.4 至 0.8mg/kg/天(他唑的初始剂量为 0.3 至 0.6mg/kg/天),具体取决于初始严重程度,最高可达 30mg。1/+++。
丙硫氧嘧啶不适合儿童格雷夫斯病。1/+++。
在开始治疗之前,可能需要进行 CBC 以评估由甲状腺功能亢进症引起的中性粒细胞减少症的程度。在随访期间不需要进行系统的 CBC。2/+。
如果出现发热或心绞痛等症状,应进行紧急 CBC。如果中性粒细胞计数<1000/mm,则应停止或减少合成抗甲状腺治疗,并在严重(<500)和持续中性粒细胞减少症时永久禁忌。否则可以恢复治疗。1/+++。
在开始治疗前应测量转氨酶水平。系统监测肝功能未得到一致验证。2/+。
如果出现黄疸、消化紊乱或瘙痒,应测量肝酶(AST、ALT)、总胆红素和结合胆红素以及碱性磷酸酶。1/+++。
应告知患者和家长抗甲状腺药物的可能副作用。1/+++。
对家长和儿童进行治疗教育对于确保最佳治疗依从性非常重要。2/+。
鉴于儿童格雷夫斯病治疗的特殊性,应由习惯于治疗儿科内分泌疾病的专家提供医疗服务。2/+。
根据患者年龄、诊断时疾病的严重程度和抗 TSH 受体抗体的持续时间,初始治疗过程必须持续 3 至 6 年。16. 应向家庭和儿童解释预期的治疗成功率(数年后治疗缓解的患者占 50%)。还应讨论可能需要根治性治疗的情况,例如治疗失败或不耐受。1/+++。
在患有格雷夫斯病的女性中,重要的是要解释她们必须在计划未来怀孕之前,从怀孕开始和怀孕期间,由内分泌科医生进行评估。即使是在药物治疗缓解后,或已接受根治性治疗的女性患者,也需要这样做。18. 根治性治疗的指征可能包括:1/++:抗甲状腺药物禁忌;由于依从性差导致甲状腺功能亢进症难以控制;尽管长期药物治疗仍复发;家庭和儿童出于个人原因要求进行治疗。
手术是儿童中 5 岁以下或甲状腺肿非常大、结节性或压迫性的情况下的根治性治疗方法。2/++。
外科医生在处理儿童甲状腺切除术方面的经验很可能是限制手术发病率的最重要决定因素(除了儿科外科医生和成人外科医生之间的任何合作之外)。1/++。
如果甲状腺肿不大,在指示进行根治性治疗时,可能会在 5 年后(但更常见的是在青春期后)讨论放射性碘治疗,如果可行。北美儿童监测格雷夫斯病的经验令人放心。1/++。